✨ Free AI Report
Biogen Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biogen Inc.
Company Research

Biogen Inc.: Business Overview, Financials & Competitive Analysis

Biogen Inc is a well-established biopharmaceutical company that focuses on discovering, developing, manufacturing, and delivering therapies for neurological, rare, and autoimmune diseases. Once the undisputed titan of...

Analyst-debate audio for Biogen Inc.

AskCyborg analysts argue the bull and bear cases for Biogen Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Transformational biotech company executing disciplined restructuring with strong pipeline catalysts in 2026, offering turnaround...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Neurology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Biogen Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Biogen Inc. Overview

Pro stress-test →

Biogen Inc is a well-established biopharmaceutical company that focuses on discovering, developing, manufacturing, and delivering therapies for neurological, rare, and autoimmune diseases. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based biotechnology pioneer is now navigating an aggressive and complex transition. The company is undergoing a strategic pivot from legacy MS drugs to a growth portfolio anchored by Alzheimer's and rare disease therapies.

Strategic Profile

Pro stress-test →

Biogen reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse. The company has successfully traded volume for value, with full year 2025 revenue at $9.9 billion and improved underlying profitability as the company shed high-cost, low-margin legacy programs. By diversifying into rare diseases and Alzheimer's, the company has stabilized its floor.

Competitive Landscape

Pro stress-test →

In Alzheimer's, Biogen and Eisai are locked in a duopoly with Eli Lilly and its drug Kisunla, with market share split nearly 50/50 as of early 2026. Novartis and Sanofi continue to squeeze Biogen's legacy portfolio with oral generics and next-generation B-cell therapies. Roche is emerging as a significant threat with experimental drug trontinemab using "Brainshuttle" technology to clear amyloid plaques faster and with fewer side effects than Leqembi.

Industry Context

Biogen Inc. operates in Biopharmaceuticals / Neurology.

Key facts

Founded: 1978 · Headquarters: Cambridge, MA, US · Employees: 7,000+ · Revenue: $9.9B · Market cap: $27.2B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Biogen Inc..

  • 2025 performance reflected continued focus on strong execution and financial discipline, driven by revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, and resilience of the MS franchise.
  • Global in-market sales for Leqembi reached $134 million in Q4 2025, a 54% increase compared to the same period in 2024, allowing Biogen to maintain a dominant 60% share of the anti-amyloid market.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Biogen reported Q4 2025 earnings beat with $2.3B revenue, exceeding expectations and raising 2026 guidance
  • February 2026FDA granted Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in cutaneous lupus
  • +1 moreTrack every material event for Biogen Inc. as it happens. Explore monitoring →
Get alerted when Biogen Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AducanumabAlzheimer's treatment (withdrawn due to controversy)→LeqembiLeading anti-amyloid Alzheimer's therapy→KisunlaCompeting anti-amyloid Alzheimer's drug→Multiple Sclerosis PortfolioNext-generation MS therapies and oral generics→

Compare Biogen Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biogen Inc. operates in Biopharmaceuticals / Neurology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Neurology research →
NEW · MCP server

Ask your AI assistant about Biogen Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biogen Inc. and its top competitor on Cyborg Score”
“What did Biogen Inc. do this quarter?”
“Is Biogen Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Biogen Inc. do?+
Biogen Inc is a well-established biopharmaceutical company that focuses on discovering, developing, manufacturing, and delivering therapies for neurological, rare, and autoimmune diseases. Once the undisputed titan of...
What is Biogen Inc.'s Cyborg Score?+
Biogen Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biogen Inc.'s main competitors?+
Named competitors include Aducanumab, Leqembi, Kisunla, Multiple Sclerosis Portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full Biogen Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biogen Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biogen Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score